HIV Infections Clinical Trial
Official title:
Research on Effect of TCM on Immune Reconstitution of HIV/AIDS Patients After HAART
Chinese prescriptions can inhibit viral replication according to the course of viral replication, and the effects is similar to the effect of HAART, and even better than the anti-viral and immune reconstitution of HAART due to its effect on improve immune system function. Over the past decades, many researchers have screened the effective Chinese medicines to treat AIDS.
- There is no record of AIDS in Chinese medicine, modern clinicians hold that AIDS is
linked to TCM theory according to its pathogenesis, character of onset and clinical
manifestations. As early as more than 2000 years ago, there were records of immune
function in TCM. 2 TCM books recorded that "keep vital Qi, the evil will not invade the
body "and" the invasion of evil is caused by the deficiency of vital Qi. Vital Qi
summarizes the normal immune system function. Vital Qi is the basic material and
physiological function which can eliminate the evil, regulating yin and yang and
protect the body.
- And this is in accordance with defense, homeostasis and surveillance of immune system
in western medicine. The knowledge of immunology has guided medical practice in China
for more than two thousand years. In response to a variety of immune diseases, there
are various immunotherapy such as Yiqi Fuzheng immunotherapy, reinforce kidney therapy,
huoxuehuayu therapy and heat-clearing and detoxifying therapy. Throughout the course of
AIDS, the evil (HIV) exists and the vital Qi is turning weak gradually. If we adopted a
number of intervention measures to assist the body's Vital Qi, Vital Qi will be
strengthened and the evil will be weakened. Therefore, TCM will play an important role
in improving immune function.
- Chinese prescriptions can inhibit viral replication according to the course of viral
replication, and the effects is similar to the effect of HAART, and even better than
the anti-viral and immune reconstitution of HAART due to its effect on improve immune
system function. Over the past decades, many researchers have screened the effective
Chinese medicines to treat AIDS.
Researchers screened single Chinese herbs, some extract and the effective components of
Chinese medicine and prescriptions. Some study the role of its anti-HIV, some study the role
of its regulating immunization function. The former studies have shown that immunization 2
(Fuzheng 2) has wide effect on immune system and it can activate the reticuloendothelial
system, macrophage phagocytes and lymphocyte transformation. And it can relieve disorders,
imbalance of the immune system caused by HIV infection.
- In addition, this prescription can inhibit HIV reverse transcription polymerase enzyme
and virus-induced syncytium formation, protect virus-infected cells, and inhibit virus
replication in HIV-1 infected cells.
- Through the clinical trials, we will evaluate the effect of immune 2 (Fuzheng 2) on
immune reconstitution of adult HIV/AIDS patients who have received HAART.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |